Innovent Biologics Inc
HKEX:1801
Innovent Biologics Inc
HKEX:1801
Price:
92.35
HKD
1.76%
Market Closed
Market Cap:
HK$160.2B
Income Statement
Earnings Waterfall
Innovent Biologics Inc
Innovent Biologics Inc
Income Statement
Innovent Biologics Inc
Innovent Biologics Inc
Currency: CNY
| Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Interest Expense |
69
|
73
|
59
|
55
|
68
|
63
|
62
|
80
|
102
|
107
|
99
|
0
|
68
|
0
|
|
| Revenue |
9
N/A
|
351
+3 599%
|
1 048
+199%
|
1 686
+61%
|
3 844
+128%
|
4 801
+25%
|
4 270
-11%
|
4 568
+7%
|
4 556
0%
|
5 018
+10%
|
6 206
+24%
|
7 457
+20%
|
9 422
+26%
|
11 423
+21%
|
|
| Gross Profit | |||||||||||||||
| Cost of Revenue |
0
|
(41)
|
(125)
|
(269)
|
(388)
|
(420)
|
(505)
|
(760)
|
(931)
|
(964)
|
(1 136)
|
(1 309)
|
(1 357)
|
(1 635)
|
|
| Gross Profit |
0
N/A
|
305
N/A
|
923
+203%
|
1 417
+54%
|
3 456
+144%
|
4 382
+27%
|
3 764
-14%
|
3 808
+1%
|
3 625
-5%
|
4 054
+12%
|
5 070
+25%
|
6 148
+21%
|
8 065
+31%
|
9 788
+21%
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(1 505)
|
(1 955)
|
(2 701)
|
(2 972)
|
(3 883)
|
(5 491)
|
(6 421)
|
(6 763)
|
(6 641)
|
(6 022)
|
(6 544)
|
(6 938)
|
(8 112)
|
(8 436)
|
|
| Selling, General & Administrative |
(356)
|
(631)
|
(1 448)
|
(1 723)
|
(1 778)
|
(2 536)
|
(3 426)
|
(3 840)
|
(3 426)
|
(3 336)
|
(3 851)
|
(4 334)
|
(5 085)
|
(5 703)
|
|
| Research & Development |
(1 222)
|
(1 472)
|
(1 295)
|
(1 432)
|
(1 851)
|
(2 018)
|
(2 323)
|
(2 523)
|
(2 871)
|
(2 620)
|
(2 112)
|
(2 396)
|
(2 202)
|
(2 120)
|
|
| Other Operating Expenses |
73
|
148
|
41
|
183
|
(253)
|
(937)
|
(672)
|
(401)
|
(343)
|
(66)
|
(581)
|
(208)
|
(825)
|
(614)
|
|
| Operating Income |
(1 495)
N/A
|
(1 646)
-10%
|
(1 778)
-8%
|
(1 555)
+13%
|
(427)
+73%
|
(1 109)
-160%
|
(2 657)
-139%
|
(2 956)
-11%
|
(3 016)
-2%
|
(1 968)
+35%
|
(1 474)
+25%
|
(791)
+46%
|
(47)
+94%
|
1 352
N/A
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
21
|
(73)
|
58
|
(55)
|
(431)
|
(148)
|
16
|
319
|
845
|
541
|
446
|
(159)
|
624
|
62
|
|
| Non-Reccuring Items |
(4 399)
|
(4 811)
|
0
|
0
|
(1)
|
(0)
|
(1)
|
(1)
|
0
|
(1)
|
(116)
|
(331)
|
(656)
|
(203)
|
|
| Pre-Tax Income |
(5 873)
N/A
|
(6 530)
-11%
|
(1 720)
+74%
|
(1 610)
+6%
|
(859)
+47%
|
(1 257)
-46%
|
(2 642)
-110%
|
(2 637)
+0%
|
(2 170)
+18%
|
(1 428)
+34%
|
(1 144)
+20%
|
(1 281)
-12%
|
(79)
+94%
|
1 211
N/A
|
|
| Net Income | |||||||||||||||
| Tax Provision |
0
|
0
|
0
|
(4)
|
(140)
|
(136)
|
(87)
|
(38)
|
(9)
|
60
|
116
|
(0)
|
(16)
|
(79)
|
|
| Income from Continuing Operations |
(5 873)
|
(6 530)
|
(1 720)
|
(1 614)
|
(998)
|
(1 394)
|
(2 729)
|
(2 676)
|
(2 179)
|
(1 368)
|
(1 028)
|
(1 281)
|
(95)
|
1 132
|
|
| Income to Minority Interest |
101
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(5 771)
N/A
|
(6 530)
-13%
|
(1 720)
+74%
|
(1 614)
+6%
|
(998)
+38%
|
(1 394)
-40%
|
(2 729)
-96%
|
(2 676)
+2%
|
(2 179)
+19%
|
(1 368)
+37%
|
(1 028)
+25%
|
(1 281)
-25%
|
(95)
+93%
|
1 132
N/A
|
|
| EPS (Diluted) |
-17.24
N/A
|
-5.66
+67%
|
-1.46
+74%
|
-1.22
+16%
|
-0.74
+39%
|
-0.97
-31%
|
-1.87
-93%
|
-1.83
+2%
|
-1.46
+20%
|
-0.9
+38%
|
-0.66
+27%
|
-0.8
-21%
|
-0.06
+93%
|
0.67
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
